Background: Chronic hypoxia-induced epithelial-to-mesenchymal transition (EMT) is a crucial process in renal fibrogenesis. Egr-1, as a transcription factor, has been proven to be important in promoting EMT. However, whether it functions in hypoxia-induced renal tubular EMT has not been fully elucidated. Methods: Egr-1 were detected at mRNA and protein levels by qPCR and Western blot analysis respectively after renal epithelial cells were subjected to hypoxia treatment. Meanwhile, EMT phenotype was also observed through identification of relevant EMT-specific markers. siRNA was used to knock down Egr-1 expression and subsequent changes were observed. Specific PKC and MAPK/ERK inhibitors were employed to determine the molecular signaling pathway involved in Egr-1-mediated EMT phenotype. In vivo assays using rat remnant kidney model were used to validate the in vitro results. Furthermore, Egr-1 expression was examined in the samples of CKD patients with the clinical relevance revealed. Results: Hypoxia treatment enhanced the mRNA and protein levels of Egr-1 in HK-2 cells, which was accompanied by a reduced expression of the epithelial marker E-cadherin and an enhanced expression of the mesenchymal marker Fsp-1. Downregulation of Egr-1 with siRNA reversed hypoxia-induced EMT. Using the specific inhibitors to protein kinase C (calphostin C) or MAPK/ERK (PD98059), we identified that hypoxia induced Egr-1 expression through the PKC/ERK pathway. In addition, the upregulation of Egr-1 raised endogenous Snail levels, and the downregulation of Snail inhibited Egr-1-mediated EMT in HK-2 cells. Through in vivo assays using rat remnant kidney and CKD patients' kidney tissues, we found that Egr-1 and Snail were overexpressed in tubular epithelial cells with EMT. Conclusion: Egr-1 may be an important regulator of the development of renal tubular EMT induced by hypoxia through the PKC/ERK pathway and the activation of Snail. Targeting Egr-1 expression or activity might be a novel therapeutic strategy to control renal fibrosis.

Keywords:
Egr-1, Hypoxia, PKC/ERK, Renal fibrosis
1.
Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
2.
Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12.
3.
Kriz W, Kaissling B, Le Hir M: Epithelial-mesenchymal transition in kidney fibrosis: fact or fantasy? J Clin Invest 2011;121:468-474.
4.
Galichon P, Finianos S, Hertig A: EMT-MET in renal disease: should we curb our enthusiasm? Cancer Lett 2013;341:24-29.
5.
Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212-222.
6.
Galichon P, Hertig A: Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside? Fibrogenesis Tissue Repair 2011;4:11.
7.
Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, et al: Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006;6:2937-2946.
8.
Sun S, Du R, Xia L, Sun W, Zhai Y, et al: Twist is a new prognostic marker for renal survival in patients with chronic kidney disease. Am J Nephrol 2012;35:141-151.
9.
Chen J, Chen JK, Harris RC: Angiotensin II induces epithelial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 2012;32:981-991.
10.
Zhang A, Jia Z, Guo X, Yang T: Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 2007;293:F723-F731.
11.
Sun S, Ning X, Zhang Y, Lu Y, Nie Y, et al: Hypoxia-inducible factor-1α induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int 2009;75:1278-1287.
12.
Sauer L, Gitenay D, Vo C, Baron VT: Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010;29:2628-2637.
13.
Kenzel S, Santos-Sierra S, Deshmukh SD, Moeller I, Ergin B, et al: Role of p38 and early growth response factor 1 in the macrophage response to group B streptococcus. Infect Immun 2009;77:2474-2481.
14.
Vazquez-Padron RI, Mateu D, Rodriguez-Menocal L, Wei Y, Webster KA, et al: Novel role of Egr-1 in nicotine-related neointimal formation. Cardiovasc Res 2010;88:296-303.
15.
Khachigian LM: Early growth response-1 in cardiovascular pathobiology. Circ Res 2006;98:186-191.
16.
Lee CG, Cho SJ, Kang MJ, et al: Early growth response gene 1-mediated apoptosis is essential for transforming growth factor-β1-induced pulmonary fibrosis. J Exp Med 2004;200:377-389.
17.
Saadane N, Alpert L, Chalifour LE: Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice. Am J Physiol Heart Circ Physiol 2000;278:H796-H805.
18.
Pritchard MT, Nagy LE: Ethanol-induced liver injury: potential roles for Egr-1. Alcohol Clin Exp Res 2005;29:146S-150S.
19.
Nakamura H, Isaka Y, Tsujie M, et al: Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial α-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction rats. Gene Ther 2002;9:495-502.
20.
Bhattacharyya S, Wu M, Fang F, et al: Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol 2011;30:235-242.
21.
Shen N, Yu X, Pan FY, et al: An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism. J Biol Chem 2011;286:14508-14515.
22.
Kim JH, Jeong IY, Lim Y, et al: Estrogen receptor-β stimulates Egr-1 transcription via MEK1/Erk/Elk-1 cascade in C6 glioma cells. BMB Rep 2011;44:452-457.
23.
Salome N, Taube M, Egecioglu E, et al: Gastrectomy alters emotional reactivity in rats: neurobiological mechanisms. Eur J Neurosci 2011;33:1685-1695.
24.
Cheng JC, Chang HM, Leung PC: Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene 2013;32:1041-1049.
25.
Bochkov VN, Mechtcheriakova D, Lucerna M, et al: Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca2+/NFAT. Blood 2002;99:199-206.
26.
Queiroz-Leite GD, Peruzzetto MC, Neri EA, et al: Transcriptional regulation of the Na+/H+ exchanger NHE3 by chronic exposure to angiotensin II in renal epithelial cells. Biochem Biophys Res Commun 2011;409:470-476.
27.
Copland IB, Kavanagh BP, Engelberts D, et al: Early changes in lung gene expression due to high tidal volume. Am J Respir Crit Care Med 2003;168:1051-1059.
28.
Yan SF, Lu J, Xu L, et al: Pulmonary expression of early growth response-1: biphasic time course and effect of oxygen concentration. J Appl Physiol 2000;88:2303-2309.
29.
Patel N, Kalra VK: Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1α (HIF-1α) in endothelial cells. J Biol Chem 2010;285:20570-20579.
30.
Ouellette AJ, Malt RA, Sukhatme VP, et al: Expression of two ‘immediate early' genes, Egr-1 and c-fos, in response to renal ischemia and during compensatory renal hypertrophy in mice. J Clin Invest 1990;85:766-771.
31.
Manotham K, Tanaka T, Matsumoto M, et al: Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004;5:1277-1288.
32.
Zhang B, Liang X, Shi W, et al: Role of impaired peritubular capillary and hypoxia in progressive interstitial fibrosis after 56 subtotal nephrectomy of rats. Nephrology (Carlton) 2005;10:351-357.
33.
Zeng R, Yao Y, Han M, et al: Biliverdin reductase mediates hypoxia-induced EMT via PI3-kinase and Akt. J Am Soc Nephrol 2008;19:380-387.
34.
National Kidney F: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
35.
Cohen DM, Gullans SR, Chin WW: Urea signaling in cultured murine inner medullary collecting duct (mIMCD3) cells involves protein kinase C, inositol 1,4,5-trisphosphate (IP3), and a putative receptor tyrosine kinase. J Clin Invest 1996;97:1884-1889.
36.
Lo LW, Cheng JJ, Chiu JJ, et al: Endothelial exposure to hypoxia induces Egr-1 expression involving PKCα-mediated Ras/Raf-1/ERK1/2 pathway. J Cell Physiol 2001;188:304-312.
37.
Luo D, Wang J, Li J, et al: Mouse snail is a target gene for HIF. Mol Cancer Res 2011;9:234-245.
38.
Grotegut S, von Schweinitz D, Christofori G, et al: Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006;25:3534-3545.
39.
Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol 2012;8:275-283.
40.
Daniel L, Saingra Y, Giorgi R, et al: Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 2000;35:13-20.
41.
Lv J, Zhang H, Zhou Y, et al: Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow-up of 204 cases in China. Nephrology (Carlton) 2008;13:242-246.
42.
Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
43.
Fine LG, Bandyopadhay D, Norman JT: Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000;75:S22-S26.
44.
Choi YJ, Chakraborty S, Nguyen V, et al: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 2000;31:1491-1497.
45.
Iwano M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004;13:279-284.
46.
Manotham K, Tanaka T, Matsumoto M, et al: Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004;65:871-880.
47.
Elbarghati L, Murdoch C, Lewis CE: Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology 2008;213:899-908.
48.
Moon Y, Bottone FG Jr, McEntee MF, et al: Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol Cancer Ther 2005;4:1551-1558.
49.
Kuo PL, Chen YH, Chen TC, et al: CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol 2011;226:1224-1231.
50.
Kobayashi D, Yamada M, Kamagata C, et al: Overexpression of early growth response-1 as a metastasis-regulatory factor in gastric cancer. Anticancer Res 2002;22:3963-3970.
51.
Lemieux E, Bergeron S, Durand V, et al: Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int J Cancer 2009;125:1575-1586.
52.
Thiel G, Cibelli G: Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002;193:287-292.
53.
Rossler OG, Thiel G: Thrombin induces Egr-1 expression in fibroblasts involving elevation of the intracellular Ca2+ concentration, phosphorylation of ERK and activation of ternary complex factor. BMC Mol Biol 2009;10:40.
54.
Haase VH: Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair 2012;(suppl 1):S16.
55.
Bachelder RE, Yoon SO, Franci C, et al: Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 2005;168:29-33.
56.
Ikenouchi J, Matsuda M, Furuse M, et al: Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci 2003;116:1959-1967.
57.
Boutet A, De Frutos CA, Maxwell PH, et al: Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J 2006;25:5603-5613.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.